Entering text into the input field will update the search result below

X4 Pharma teams up with blood cancer charity to advance mavorixafor

May 15, 2019 11:30 AM ETX4 Pharmaceuticals, Inc. (XFOR) StockXFORBy: Douglas W. House, SA News Editor
  • X4 Pharmaceuticals (XFOR +0.5%) will collaborate with the Leukemia & Lymphoma Society (LLS), a nonprofit charitable organization dedicated to curing blood cancers, to accelerate the development of lead candidate mavorixafor (X4P-001) for the treatment of a B-cell malignancy called Waldenström’s macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma that occurs in about 1,400 Americans each year.
  • The company will conduct a Phase 1/2 study assessing mavorixafor, a small molecule inhibitor of a protein called chemokine receptor type 4 (CXCR4) that plays a key role in cancer cell survival and growth, combined with AbbVie's (and J&J's) Imbruvica (ibrutinib) in WM patients. LLS will provide guidance and advice during the trial.

Recommended For You

More Trending News

About XFOR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
XFOR--
X4 Pharmaceuticals, Inc.